Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Worldwide Offices
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Neuromod Launches Online Tinnitus Masterclass


News provided by

Neuromod Devices

21 Oct, 2025, 05:30 GMT

Share this article

Share toX

Share this article

Share toX

  • Neuromod has launched Tinnitus Masterclass, an online course that features a blend of medical and commercial tinnitus modules.
  • Tinnitus Masterclass is aimed at audiologists and ENTs in Europe who wish to offer, or expand, tinnitus care in their clinic.
  • Tinnitus Masterclass improves tinnitus care accessibility by providing hearing care professionals with expert knowledge to introduce tinnitus care in their clinic.

DUBLIN, Oct. 21, 2025 /PRNewswire/ -- Neuromod, the medical device company that created the Lenire tinnitus treatment device, has launched Tinnitus Masterclass, an online course that provides hearing care professionals with expert clinical and commercial knowledge to introduce effective and sustainable tinnitus care services in their clinic.

Continue Reading
This image opens in the lightbox
Neuromod Founder and CEO, Dr. Ross O'Neill

Tinnitus Masterclass is an expert-led online course that blends audiology, neurology, and psychology with short, focused modules that cover tinnitus aetiology, assessment, treatment options, and patient guidance. To support the commercial viability of tinnitus services in clinical practice, Tinnitus Masterclass also features modules on economics of tinnitus, defining service offerings, and marketing specialised tinnitus care.

Tinnitus Masterclass Increases Tinnitus Care Accessibility

Tinnitus, which is commonly known as ringing in the ears, is a complex medical condition that impacts approximately 15% of the global adult population1. Despite this prevalence, nearly half of all tinnitus patients had to wait more than two months or more for specialist tinnitus care per a 2024 Tinnitus UK report2.

Neuromod's Director of Clinical Affairs and Tinnitus Masterclass coordinator, Dr. Jakob Kümmel, believes that Tinnitus Masterclass helps to grow access to tinnitus services:

"Neuromod created the Tinnitus Masterclass to empower hearing-care professionals with the knowledge, confidence, and tools to deliver truly patient-centered tinnitus care," said Dr. Kümmel. "Our goal is to raise the standard of tinnitus care globally - enabling clinicians to bridge science, evidence, and empathy while developing models of care that are both effective for patients, and viable for their practices."

A Tinnitus Curriculum Developed by Experts

Tinnitus Masterclass was developed by Neuromod in collaboration with leading tinnitus clinicians, researchers, and business professionals.

Contributors include Dr. Jason Leyendecker AuD, Academy of Doctors of Audiology Past President and Tinnitus & Hyperacusis Clinic owner, Dr. Melissa Wikoff AuD, Peachtree Audiology owner, Dr. Emily E. McMahan, Audiology Practice Standards Organization President and Alaska Hearing & Tinnitus Center owner, Prof. Gail Whitelaw, American Academy of Audiology Past President and Speech-Language-Hearing Clinic Director at The OSU, and Dr. Jennifer Gans PhD, Mindfulness Based Tinnitus Stress Reduction creator.

The access-anywhere course combines expertise from experienced tinnitus practitioners with Neuromod's experience from delivering tinnitus training to hundreds of hearing healthcare professionals, and conducting extensive research in the field of tinnitus.

Neuromod has conducted three large scale clinical trials for Lenire, the first and only FDA approved bimodal neuromodulation tinnitus treatment device. These trials demonstrated the effectiveness and safety of Lenire across more than 600 tinnitus patients.3,4,5,

Lenire's real world effectiveness is consistent with outcomes reported by patients in Lenire's large-scale clinical trials.6 These results are owed to a combination of clinical expertise, and rigorous training delivered by Neuromod.

In addition to successful patient outcomes, practices providing specialised tinnitus care, such as Lenire, have grown their patient-base and commercially matured their business.

"Demand for tinnitus care from expert clinicians is significant. Building the knowledge and confidence of clinicians interested in helping tinnitus patients is critical to serving the global patient population," said Dr. Ross O'Neill PhD, Neuromod Founding CEO.

"Tinnitus Masterclass delivers this by combining expertise from some of the most experienced tinnitus clinicians practising today with Neuromod's significant experience training audiology and ENT practices in clear, practical lessons".

Enrol in Tinnitus Masterclass

Hearing healthcare professionals who wish to introduce or expand tinnitus care services in their clinic can register for Tinnitus Masterclass at neuromod.com/tinnitus-masterclass.

Tinnitus Masterclass is accessible via web browser or mobile app on iOS or Android. Tinnitus Masterclass is currently available to European healthcare professionals in English with additional languages and regions in development.

About Neuromod

Founded in 2010, Neuromod Devices is a global medical technology company with offices in Ireland, Germany and America. Neuromod specialises in the design and development of neuromodulation technologies to address the clinical needs of underserved patient populations.

The lead application of Neuromod's technology is in the field of tinnitus. Neuromod has completed extensive clinical trials to confirm the efficacy of its non-invasive neuromodulation platform in this common disorder. For more information visit www.neuromod.com.

References

  1. Tinnitus UK, Struggle for Silence Report, https://tinnitus.org.uk/wp-content/uploads/2024/02/TINNITUS-WEEK-2024-REPORT-V8c.pdf (2024).
  2. Global Prevalence and Incidence of Tinnitus. A Systematic Review and Meta-analysis, JAMA (2022).
  3. Conlon, B. et al. Different bimodal neuromodulation settings reduce tinnitus symptoms in a large randomized trial. Scientific Reports 12, 10845 (2022).
  4. Conlon, B. et al. Bimodal neuromodulation combining sound and tongue stimulation reduces tinnitus symptoms in a large randomized clinical study. Science Translational Medicine 12, eabb2830 (2020).
  5. Boedts M, B. A., Khoo G, et al. Combining sound with tongue stimulation clinically improves tinnitus symptoms in a controlled pivotal trial. Nature Communications (2024).
  6. Mc Mahan, E., Lim, H. Retrospective chart review demonstrating effectiveness of bimodal neuromodulation for tinnitus treatment in a clinical setting Commun Med (2025). https://doi.org/10.1038/s43856-025-00837-3

Photo - https://mma.prnewswire.com/media/2800889/Dr_Ross_O_Neill.jpg

Modal title

Also from this source

Neuromod Advance Multiple Regulatory Approvals to Expedite Global Availability of Lenire

Neuromod Advance Multiple Regulatory Approvals to Expedite Global Availability of Lenire

Neuromod Devices, the medical device company that created the Lenire® tinnitus treatment device, has announced approval to the Medical Device Single...

Nature Communications Medicine Publishes Positive, Real World Data for Tinnitus Patients Treated with Unique, FDA Approved Stimulation Device

Nature Communications Medicine Publishes Positive, Real World Data for Tinnitus Patients Treated with Unique, FDA Approved Stimulation Device

Nature Communications Medicine has published the first peer reviewed, real-world analysis of U.S. patients treated with Lenire, the only FDA approved ...

More Releases From This Source

Explore

Health Care & Hospitals

Health Care & Hospitals

Medical Pharmaceuticals

Medical Pharmaceuticals

Medical Equipment

Medical Equipment

New Products & Services

New Products & Services

News Releases in Similar Topics

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • PR Newswire Amplify™
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.